Brief: Exelixis Says Cabometyx Reduced Risk Of Disease Progression Or Death By 81% Versus Placebo In Patients With Advanced Lung Or Thymic Neuroendocrine Tumors
18/10/2025 08:13
Oct 18 (Reuters) - Exelixis Inc EXEL.O: EXELIXIS ANNOUNCES RESULTS FROM SUBGROUP ANALYSIS OF CABINET PHASE 3 PIVOTAL TRIAL EVALUATING CABOMETYX® (CABOZANTINIB) IN ADVANCED LUNG AND THYMIC NEUROENDOCRINE TUMORS AT ESMO 2025 EXELIXIS: CABOMETYX REDUCED RISK OF DISEASE PROGRESSION OR DEATH BY 81% VERSUS PLACEBO IN PATIENTS WITH ADVANCED LUNG OR THYMIC NEUROENDOCRINE TUMORS Source text: ID:nBwG69jSa Further company coverage: EXEL.O ((Reuters.Briefs@thomsonreuters.com;))